Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer

Powell, Adam C.; Mirhadi, Amin; Loy, Bryan A.; Happe, Laura E.; Long, James W.; Kren, Erin M.; Gupta, Amit

doi:10.1371/journal.pone.0181319

Cited by 3 publications

(2 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A lung nodule flagger can potentially change the rate at which lab tests and biopsies are conducted and the rate at which patients receiving images progress to receiving surgery, radiation therapy, or chemotherapy. Prior research has shown that asymptomatic patients which are diagnosed with lung cancer have very different patterns of downstream service utilization from symptomatic patients (4). To the extent that AI enables patients to be more likely to receive diagnoses before they progress to being symptomatic, there may be a reduction in the utilization of downstream services.…”

Section: Downstream Costsmentioning

confidence: 99%

Impact of the Artificial Nudge

Powell

2020

Academic Radiology

Self Cite

View full text Add to dashboard Cite

Section: Downstream Costsmentioning

confidence: 99%

Impact of the Artificial Nudge

Powell

2020

Academic Radiology

Self Cite

View full text Add to dashboard Cite

“…In China, the morbidity (20.48%) and mortality (40.71%) of lung cancer rank as the first among all malignant tumors, representing a great threat to public health ( 2 ). Studies have demonstrated that non-small cell lung cancer (NSCLC), as the main clinical pathological type, accounts for ~90% of lung cancer cases ( 3 – 5 ). Due to the difficulty for the early diagnosis of NSCLC, distant metastasis occurs in ~40% of patients at the first diagnosis, whereas 50% of patients in the treatment process suffer from tumor metastasis ( 6 ).…”

Section: Introductionmentioning

confidence: 99%

Role of miR‑520b in non‑small cell lung cancer

Zhang

2018

Exp Ther Med

View full text Add to dashboard Cite

The aim of the present study was to investigate the expression of microRNA (miR)-520b in non-small cell lung cancer (NSCLC) and its biological functions. Reverse transcription-quantitative polymerase chain reaction was used to detect the expression of miR-520b in 52 cases of NSCLC tissues, and its associations with tumor clinical staging and lymph node metastasis were analyzed. miR-520b mimics was transfected into A549 and Calu-3 cells. Cell proliferation, cell cycle, and cell invasion and migration abilities were assessed via cell counting kit-8 assay, flow cytometry and Transwell chamber assay, respectively. Western blot analysis was performed to detected protein expression levels, and dual luciferase reporter assay was used to detect the gene interaction. miR-520b expression was significantly downregulated in NSCLC. The expression of miR-520b in tumor tissues at N1 stage was lower than that at the N0 stage. miR-520b expression was negatively associated with clinical TNM staging. Furthermore, miR-520b mimic transfection inhibited the proliferation and invasion and metastasis abilities of A549 and Calu-3 cells. The expression of Rab22A was downregulated in the miR-520b mimics-transfected cells, whereas E-cadherin expression was increased, and vimentin expression was downregulated. Dual luciferase reporter assay demonstrated that miR-520b directly targeted the expression of Rab22A. Furthermore, Rab22A reversal downregulated the inhibitory effect of miR-520b. miR-520b expression was downregulated in NSCLC, which was negatively correlated with lymph node metastasis and TNM staging. miR-520b targeted on Rab22A to work as a tumor suppressor, inhibiting tumor proliferation and metastasis.

show abstract

Recent advances in radiation therapy and photodynamic therapy

Chong

Tng

Tan

et al. 2021

Applied Physics Reviews

View full text Add to dashboard Cite

In the past 100 years, external beam energy for the treatment of cancer has continually evolved. Two main modes have been developed. The first is radiotherapy which involves using x-ray, gamma, and proton beams to cause ionizing damage. The second is photodynamic therapy, which uses photons to activate photosensitizers to generate reactive oxidating species causing cytotoxicity. For decades, these two fields have developed separately, with photodynamic therapy being used for treating surface tumors and radiotherapy, for deeper tumors. In the first half of this article, a detailed review of radiotherapy and photodynamic therapy will be presented. For each field, the underlying physical mechanisms will be discussed, followed by the existing technological and engineering designs, and ending off with the relevant vivo studies and clinical applications. In the second half, the recent efforts to combine radiotherapy and photodynamic therapy, leading to the generation of new techniques such as x-ray photodynamic therapy, proton-induced photodynamic therapy and even the possibility of hybrid approaches such as intensity and fluence modulated photodynamic therapy will be discussed. This new field is known as radiodynamic therapy. It has the potential to achieve increased conformality in the treatment of cancer, dealing maximal dosage to the lesion while sparing healthy tissues, paving the way for new advances in precision medicine. The connection between these fields is a neglected area, and this review addresses this gap. It also serves as a repository for researchers who are keen to venture into radiodynamic therapy.

show abstract

Presentation at computed tomography (CT) scan of the thorax and first year diagnostic and treatment utilization among patients diagnosed with lung cancer

Cited by 3 publications

References 13 publications

Impact of the Artificial Nudge

Impact of the Artificial Nudge

Role of miR‑520b in non‑small cell lung cancer

Recent advances in radiation therapy and photodynamic therapy

Contact Info

Product

Resources

About